Societal CDMO Signs Manufacturing and Supply Agreement with InfectoPharm

Societal CDMO has signed a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA in Europe.

Societal CDMO announced on May 5, 2022 that it has entered a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA capsules (methylphenidate hydrochloride extended-release capsules) in Europe. The agreement establishes Societal CDMO as the exclusive supplier of Ritalin LA capsules for the European market through 2023.

Societal CDMO had served as Novartis’ exclusive global supplier of Ritalin LA and Focalin XR capsules for approximately 20 years, and Novartis has given European rights to Ritalin LA capsules to InfectoPharm. The new agreement will maintain Societal CDMO’s role as the exclusive supplier of Ritalin LA in Europe. The company’s exclusive Manufacturing and Supply Agreement with Novartis remains unchanged for the rest of the world and will continue through 2023.

“Societal has a long history and know-how with Ritalin, dating back to the company’s innovative formulation work that allowed for the creation of an extended-release version of the product. Over the years, we’ve enjoyed an excellent relationship with Novartis while serving as the exclusive global supplier of Ritalin LA capsules,” said David Enloe, CEO of Societal CDMO, in a press release. “We now look forward to delivering the same high-quality supply and manufacturing services to the InfectoPharm team to support the company’s commercial efforts for the product in the European market.”

Source: Recro